Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

Clinical trial NCT05960773 · SUSPENDED

Trial details

NCT number: NCT05960773
Sponsor: National Cancer Institute (NCI)
Status: SUSPENDED
Phase: Phase 2
Study type: INTERVENTIONAL

Mesothelioma Malignant Mesothelioma (MM)Early-stage Mesothelioma Subclinical Mesothelioma BRCA1-Associated Protein-1 (BAP1) Mutations Early-stage BAP1-associated Malignancies

Start date: 2024-01-31
Primary completion: 2026-12-01
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.